Polpharma Group participated in CPHI Milan 2026, one of the world’s most important pharmaceutical industry events, bringing together more than 62,000 participants and nearly 2,900 exhibitors from over 160 countries. Hosted at Fiera Milano, the event serves as a global meeting point for pharmaceutical manufacturers, API producers, biotech companies, CDMOs, suppliers, innovators and business leaders from across the healthcare value chain.
For Polpharma, CPHI is much more than a trade fair. It is a strategic platform for building new partnerships, exploring emerging technologies and engaging in discussions that shape the future of the pharmaceutical industry. The event brings together organizations involved in every stage of the value chain, from active pharmaceutical ingredients and advanced manufacturing technologies to finished medicines, quality assurance, regulatory affairs and supply chain management.
Showcasing Polpharma’s integrated capabilities
Throughout the three-day event, Polpharma representatives met with existing and prospective partners from around the world to discuss opportunities across APIs, finished dosage forms, contract development and manufacturing services, consumer healthcare and pharmaceutical innovation. The Group’s presence reflected its position as a diversified healthcare and pharmaceutical organization with capabilities spanning development, manufacturing and commercialization.
The Polpharma delegation was led by Sebastian Szymanek, CEO of Polpharma Group, together with senior leaders representing key business areas across the organization. The team engaged in a series of meetings focused on business development, strategic partnerships and future growth opportunities.
Addressing the future of pharmaceuticals
CPHI Milan 2026 focused on many of the challenges and opportunities currently transforming the pharmaceutical sector, including innovation, artificial intelligence, sustainability, supply-chain resilience and advanced manufacturing. The programme featured expert discussions and industry forums dedicated to the future of healthcare and pharmaceutical production.
These topics closely align with Polpharma’s long-term priorities. The Group continues to invest in technology, manufacturing excellence, research and development, and advanced pharmaceutical platforms. As highlighted in the message prepared for CPHI by Jerzy Starak, Founder and Chairman of the Supervisory Board of Polpharma Group, today’s pharmaceutical industry must combine quality, reliability, technological maturity and operational resilience to ensure patients’ access to safe and effective therapies.
Polpharma is also expanding capabilities across advanced technologies, including APIs, oligonucleotides, peptides and RNA-based solutions, while continuing to strengthen its expertise in pharmaceutical development and manufacturing.
Building relationships that create value
For international business partners, CPHI remains one of the most important forums for identifying new opportunities and establishing long-term collaboration. During the event, Polpharma held discussions with partners from across global markets, focusing on how to jointly address evolving healthcare needs, strengthen supply security and accelerate the development and commercialization of high-quality pharmaceutical products.
As the pharmaceutical industry continues to evolve, collaboration has never been more important. By bringing together expertise from across the healthcare ecosystem, CPHI creates an environment where innovation can be translated into practical solutions that benefit patients worldwide.
Polpharma’s presence at CPHI Milan 2026 reflects the Group’s commitment to being a reliable long-term partner, combining scientific expertise, manufacturing excellence and international experience to help shape the future of healthcare.
